Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 133

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 133
---
 evaluating BRY805 (BioRay Pharmaceutical Co.) as monotherapy in patients with solid tumours. A Phase 1/2 trial evaluating BMS-986315 (Bristol-Myers Squibb) as a monotherapy or in combination with nivolumab or cetuximab in patients with solid tumors has been completed. Exelis and Invenra are collaborating to develop a bispecific targeting PD-L1 and NKG2A which is in the preclinical setting.

There are also several pharmaceutical and biotechnology companies that are focused on the tumor microenvironment, including the complement and the adenosine pathways. AstraZeneca has an anti-CD73, Oleclumab, in Phase 3 in the PACIFIC-9 trial, in which Monalizumab is also being evaluated. I-Mab (Ulidlimab) and Arcus Biosciences (Quemliclustat) also have CD73 inhibitors in clinical development. Several other companies are developing CD39 inhibitors, including Trishula Therapeutics (TTX-030), Arcus Biosciences (AB598), and Elpiscience (ES002).

NK cells have been increasingly researched and the Company is aware of several companies activating and /or harnessing NK cells to target and kill cancer cells through different approaches such as cell therapies (for example, Fate Therapeutics, Inc. and NKarta, Inc., Century Therapeutics) and multi-specifics (for example, Affimed N. V. and Dragonfly Therapeutics, Inc.).

The development of antibody-drug conjugates (ADCs) in oncology is highly competitive, with numerous companies investing in this therapeutic approach to improve the efficacy and selectivity of cancer treatments. Nectin-4 (N4) is garnering increasing interest due to its high expression in several solid tumors, including urothelial carcinoma. To date, only one Nectin-4-targeting ADC has been commercialized (Enfortumab Vedotin, PADCEV®). Several Nectin-4-targeting ADCs conjugated with MMAE are in advanced stages of development, such as candidates from Bicycle and Mabwell. Additionally, new ADCs using topoisomerase inhibitors as cytotoxic payloads are being developed, with early-stage programs in the U. S. and Europe, and more advanced phases in China (Hengrui). In this competitive landscape, IPH4502 offers differentiated perspectives in terms of therapeutic index and potential benefit for